Product Description
Experience flawless results in oncology care with Zydus Bevacizumab Injection Bryxta 400 Mg. Designed as a valiant solution against multiple cancers, including metastatic colorectal, lung, and ovarian cancers, it is administered via intravenous infusion for targeted precision. Each triumphant dose, delivered from a secure glass vial with a rubber stopper, must be diluted with 0.9% sodium chloride prior to use. Value-driven and approved in India, this agent exemplifies pharmaceutical excellence. Add to Cart today to find a proven anti-VEGF treatment fostered by rigorous safety and regulatory standards. Prescription only.
Application and Features for Oncology Care
Zydus Bevacizumab Injection Bryxta 400 Mg is used by healthcare professionals for the treatment of various cancers, including non-small cell lung, renal cell carcinoma, and glioblastoma. Application is restricted to controlled hospital settings, ensuring safety and monitoring. Its recombinant, humanized monoclonal antibody feature targets VEGF, offering a potent anti-cancer approach. The injection's flawless formulation supports valiant clinical outcomes when used as part of a comprehensive treatment regime.
Domestic Market and Certainty in Supply
Zydus Bevacizumab Injection Bryxta 400 Mg serves the main domestic market across India, backed by stringent certifications for safety and efficacy. Packaging is delivered in a single-use, glass vial with rubber stopper and aluminum seal, maintaining sterility. For hospitals or clinics seeking quotation, simply submit a Purchase Order for swift fulfillment. Our distribution ensures reliable access, fortifying the domestic mar sector with trusted oncology solutions.
FAQ's of Zydus Bevacizumab Injection Bryxta 400 Mg:
Q: How should Zydus Bevacizumab Injection Bryxta 400 Mg be administered?
A: This injection must be given as an intravenous infusion, under the supervision of qualified healthcare professionals, in a clinical setting. The vial's medication should first be diluted with 0.9% sodium chloride before administration.
Q: What are the main indications for using Bryxta 400 Mg?
A: Zydus Bryxta 400 Mg is indicated for metastatic colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical cancer, and ovarian cancer, among other malignancies.
Q: When should Bryxta 400 Mg not be used?
A: This medication should not be used in individuals with known hypersensitivity to Bevacizumab, during pregnancy, or in cases of severe infections. It requires a doctor's prescription and must only be administered as directed.
Q: What is the composition and packaging of Bryxta 400 Mg?
A: Each vial contains 400 mg of Bevacizumab in a clear to slightly opalescent solution. It comes as a single-use glass vial with a rubber stopper and aluminum seal, to be stored at 2C to 8C, protected from light, and not frozen.
Q: How can healthcare institutions place a purchase order for Zydus Bryxta 400 Mg?
A: Hospitals and authorized healthcare providers can request a quotation and place a purchase order through designated suppliers and distributors across India.
Q: What are the storage and handling instructions for Bryxta 400 Mg?
A: Store the injection between 2C and 8C, avoid freezing, and keep the vial protected from light. Only trained personnel should manage and administer this product.